Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics, S.A. announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline personality Disorder (BPD), as an oral presentation at the 37thEuropean College of Neuropsychopharmacology (ECNP) annual conference, to be held on September 21-23, 2024 in Milan, Italy. Dr. Michael Ropacki, Oryzon's Chief Medical Officer, Head of CNS Clinical Development, will be presenting the results at the ECNP New Medication Symposium on September 23rd. The oral communication is entitled "Final Results: PORTICO a double-blind, randomized placebo-controlled, adaptive phase IIb trial to assess vafidemstat's efficacy in treating borderline personality disorder".

Following this oral presentation at ECNP, the results will be subsequently published in a peer-reviewed medical journal. The company has requested the FDA an End-Of-Phase 2 meeting to discuss the design of a registrational Phase III trial with vafidemstat in BPD.